THC Farmaceuticals Inc
OTC:CBDG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (88.4), the stock would be worth $0.02 (9% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 97.4 | $0.02 |
0%
|
| 3-Year Average | 88.4 | $0.02 |
-9%
|
| 5-Year Average | 134.3 | $0.02 |
+38%
|
| Industry Average | 1.8 | $0 |
-98%
|
| Country Average | 3 | $0 |
-97%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
THC Farmaceuticals Inc
OTC:CBDG
|
299.4k USD | 97.4 | -4.9 | |
| US |
|
Cintas Corp
NASDAQ:CTAS
|
70.4B USD | 6.6 | 36.4 | |
| US |
|
Copart Inc
NASDAQ:CPRT
|
31.9B USD | 5.8 | 20.5 | |
| AU |
|
Brambles Ltd
ASX:BXB
|
29.9B AUD | 3.4 | 21.4 | |
| CA |
|
Ritchie Bros Auctioneers Inc
TSX:RBA
|
27B CAD | 4.8 | 52.2 | |
| US |
|
RB Global Inc
F:J1F
|
16.3B EUR | 4.7 | 51.5 | |
| US |
|
Aurora Innovation Inc
NASDAQ:AUR
|
9.5B USD | 2 776.8 | -11.7 | |
| FR |
|
Spie SA
PAR:SPIE
|
8.3B EUR | 0.9 | 46.9 | |
| FR |
|
Elis SA
PAR:ELIS
|
6B EUR | 2 | 16.5 | |
| DK |
|
Iss A/S
CSE:ISS
|
36.9B DKK | 0.5 | 14 | |
| US |
I
|
IAA Inc
F:3NI
|
4.9B EUR | 3.2 | 19.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
THC Farmaceuticals Inc
Glance View
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona. The company went IPO on 2012-08-22. The firm through its subsidiary CBDual Biotechnology Corp., a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The firm is engaged cannabis formulations, edibles, and delivery systems of cannabis. The company manufactures and markets cannabis extract products made from cannabis. The firm's facility is located in Southern California. The company provides access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. The firm is focusing on the research of psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations.
